Correction to: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England (Applied Health Economics and Health Policy, (2025), 23, 1, (5-17), 10.1007/s40258-024-00924-x)

Beth Woods; Ben Kearns; Laetitia Schmitt; Dina Jankovic; Claire Rothery; Sue Harnan; Jean Hamilton; Alison Scope; Shijie Ren; Laura Bojke; Mark Wilcox; William Hope; Colm Leonard; Philip Howard; David Jenkins; Alan Ashworth; Andrew Bentley; Mark Sculpher

doi:10.1007/s40258-025-00979-4

Correction to: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England (Applied Health Economics and Health Policy, (2025), 23, 1, (5-17), 10.1007/s40258-024-00924-x)

Beth Woods^*, Ben Kearns, Laetitia Schmitt, Dina Jankovic, Claire Rothery, Sue Harnan, Jean Hamilton, Alison Scope, Shijie Ren, Laura Bojke, Mark Wilcox, William Hope, Colm Leonard, Philip Howard, David Jenkins, Alan Ashworth, Andrew Bentley, Mark Sculpher

^*Corresponding author for this work

Centre for Health Economics

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The article “Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime‑Avibactam to Inform Delinked Payments by the NHS in England”, written by Beth Woods, Ben Kearns, Laetitia Schmitt, Dina Jankovic, Claire Rothery, Sue Harnan, Jean Hamilton, Alison Scope, Shijie Ren, Laura Bojke, Mark Wilcox, William Hope, Colm Leonard, Philip Howard, David Jenkins, Alan Ashworth, Andrew Bentley, and Mark Sculpher, was originally published under exclusive license to Springer Nature Switzerland AG.

Original language	English
Number of pages	2
Journal	Applied Health Economics and Health Policy
DOIs	https://doi.org/10.1007/s40258-025-00979-4
Publication status	E-pub ahead of print - 2 Jun 2025

Bibliographical note

Publisher Copyright:
© The Author(s) 2025.

Access to Document

10.1007/s40258-025-00979-4Licence: CC BY-NC

Cite this

Woods, B., Kearns, B., Schmitt, L., Jankovic, D., Rothery, C., Harnan, S., Hamilton, J., Scope, A., Ren, S., Bojke, L., Wilcox, M., Hope, W., Leonard, C., Howard, P., Jenkins, D., Ashworth, A., Bentley, A., & Sculpher, M. (2025). Correction to: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England (Applied Health Economics and Health Policy, (2025), 23, 1, (5-17), 10.1007/s40258-024-00924-x). Applied Health Economics and Health Policy. Advance online publication. https://doi.org/10.1007/s40258-025-00979-4

@article{d2056af9c9c74cda83e1b43d0817c2c0,

title = "Correction to: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England (Applied Health Economics and Health Policy, (2025), 23, 1, (5-17), 10.1007/s40258-024-00924-x)",

abstract = "The article “Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime‑Avibactam to Inform Delinked Payments by the NHS in England”, written by Beth Woods, Ben Kearns, Laetitia Schmitt, Dina Jankovic, Claire Rothery, Sue Harnan, Jean Hamilton, Alison Scope, Shijie Ren, Laura Bojke, Mark Wilcox, William Hope, Colm Leonard, Philip Howard, David Jenkins, Alan Ashworth, Andrew Bentley, and Mark Sculpher, was originally published under exclusive license to Springer Nature Switzerland AG.",

author = "Beth Woods and Ben Kearns and Laetitia Schmitt and Dina Jankovic and Claire Rothery and Sue Harnan and Jean Hamilton and Alison Scope and Shijie Ren and Laura Bojke and Mark Wilcox and William Hope and Colm Leonard and Philip Howard and David Jenkins and Alan Ashworth and Andrew Bentley and Mark Sculpher",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = jun,

day = "2",

doi = "10.1007/s40258-025-00979-4",

language = "English",

journal = "Applied Health Economics and Health Policy",

issn = "1175-5652",

publisher = "Springer",

}

Woods, B, Kearns, B, Schmitt, L , Jankovic, D , Rothery, C, Harnan, S, Hamilton, J, Scope, A, Ren, S, Bojke, L, Wilcox, M, Hope, W, Leonard, C, Howard, P, Jenkins, D, Ashworth, A, Bentley, A & Sculpher, M 2025, 'Correction to: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England (Applied Health Economics and Health Policy, (2025), 23, 1, (5-17), 10.1007/s40258-024-00924-x)', Applied Health Economics and Health Policy. https://doi.org/10.1007/s40258-025-00979-4

Correction to: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England (Applied Health Economics and Health Policy, (2025), 23, 1, (5-17), 10.1007/s40258-024-00924-x). / Woods, Beth; Kearns, Ben; Schmitt, Laetitia et al.
In: Applied Health Economics and Health Policy, 02.06.2025.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Correction to

T2 - Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England (Applied Health Economics and Health Policy, (2025), 23, 1, (5-17), 10.1007/s40258-024-00924-x)

AU - Woods, Beth

AU - Kearns, Ben

AU - Schmitt, Laetitia

AU - Jankovic, Dina

AU - Rothery, Claire

AU - Harnan, Sue

AU - Hamilton, Jean

AU - Scope, Alison

AU - Ren, Shijie

AU - Bojke, Laura

AU - Wilcox, Mark

AU - Hope, William

AU - Leonard, Colm

AU - Howard, Philip

AU - Jenkins, David

AU - Ashworth, Alan

AU - Bentley, Andrew

AU - Sculpher, Mark

PY - 2025/6/2

Y1 - 2025/6/2

N2 - The article “Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime‑Avibactam to Inform Delinked Payments by the NHS in England”, written by Beth Woods, Ben Kearns, Laetitia Schmitt, Dina Jankovic, Claire Rothery, Sue Harnan, Jean Hamilton, Alison Scope, Shijie Ren, Laura Bojke, Mark Wilcox, William Hope, Colm Leonard, Philip Howard, David Jenkins, Alan Ashworth, Andrew Bentley, and Mark Sculpher, was originally published under exclusive license to Springer Nature Switzerland AG.

AB - The article “Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime‑Avibactam to Inform Delinked Payments by the NHS in England”, written by Beth Woods, Ben Kearns, Laetitia Schmitt, Dina Jankovic, Claire Rothery, Sue Harnan, Jean Hamilton, Alison Scope, Shijie Ren, Laura Bojke, Mark Wilcox, William Hope, Colm Leonard, Philip Howard, David Jenkins, Alan Ashworth, Andrew Bentley, and Mark Sculpher, was originally published under exclusive license to Springer Nature Switzerland AG.

UR - http://www.scopus.com/inward/record.url?scp=105007156229&partnerID=8YFLogxK

U2 - 10.1007/s40258-025-00979-4

DO - 10.1007/s40258-025-00979-4

M3 - Comment/debate

AN - SCOPUS:105007156229

SN - 1175-5652

JO - Applied Health Economics and Health Policy

JF - Applied Health Economics and Health Policy

ER -

Woods B, Kearns B, Schmitt L , Jankovic D , Rothery C, Harnan S et al. Correction to: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England (Applied Health Economics and Health Policy, (2025), 23, 1, (5-17), 10.1007/s40258-024-00924-x). Applied Health Economics and Health Policy. 2025 Jun 2. Epub 2025 Jun 2. doi: 10.1007/s40258-025-00979-4

Correction to: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England (Applied Health Economics and Health Policy, (2025), 23, 1, (5-17), 10.1007/s40258-024-00924-x)

Abstract

Bibliographical note

Access to Document

Other files and links

Cite this